Antiretroviral manufacturers and the challenge of universal access to drugs through the Brazilian National STD/AIDS Program.
This article describes the antiretroviral (ARV) manufacturing market in Brazil and contextualizes the challenges for the public policy of supplying ARVs through the National STD/AIDS Program. Increasing expenditure on these drugs is the main source of uncertainty for the policy's future. Brazil's domestic scenario is one of growing external dependence, both for the finished drugs and the active ingredients. Experience in the National Program has shown that it is the state's role to provide public goods, which presupposes ensuring mutual compatibility between company interests and social interests. This balance is currently at stake in Brazil, since structural changes in the market have raised challenges for the National Program's sustainability, requiring new public policy instruments in defense of the collective interest. The article drew on a literature review, using bibliographic indexing sources, systematic organization of primary data, government publications, relevant legislation, research reports, and articles recommended by experts from the field.
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil. regina.ferro.lago@gmail.com
Regina Ferro
RF
do Lago
Nilson do Rosário
Ndo R
Costa
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000600:supply & distribution* / Q000627:therapeutic use; D001938:Brazil; D004345:Drug Industry / Q000706:statistics & numerical data*; D006297:Health Services Accessibility / Q000706:statistics & numerical data; D006801:Humans; D009313:National Health Programs / Q000191:economics*
D019380:Anti-HIV Agents